Hemoglobin and hematocrit experienced similar increases in both groups : from 8.5 + / - 0.9 g/dL and 25.8 + / - 2.7 % to 11.7 + / - 0.6 g/dL and 34.7 + / - 1.6 % ( P < 0.001 ) in patients receiving rHuEPO , and from 8.9 + / - 0.8 and 27 + / - 2.2 % to 11.8 + / - 0.4 g/dL and 35.1 + / - 1.5 % ( P < 0.001 ) in subjects treated with ND .
